Axsome Therapeutics
AXSM
353 hedge funds and large institutions have $4.37B invested in Axsome Therapeutics in 2025 Q1 according to their latest regulatory filings, with 91 funds opening new positions, 103 increasing their positions, 115 reducing their positions, and 28 closing their positions.
225% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 28
39% more capital invested
Capital invested by funds: $3.15B → $4.37B (+$1.22B)
29% more call options, than puts
Call options by funds: $111M | Put options by funds: $86.5M
21% more funds holding
Funds holding: 292 → 353 (+61)
9% more funds holding in top 10
Funds holding in top 10: 11 → 12 (+1)
0.06% more ownership
Funds ownership: 76.73% → 76.79% (+0.06%)
10% less repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 115
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$71.1M |
| 2 |
D.E. Shaw & Co
New York
|
+$60.1M |
| 3 |
O
OrbiMed
New York
|
+$44.1M |
| 4 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$41.4M |
| 5 |
Man Group
London,
United Kingdom
|
+$39.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$129M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$84.6M |
| 3 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$74.5M |
| 4 |
Lazard Asset Management
New York
|
-$57.9M |
| 5 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
-$54.6M |
AXSM Hedge Fund Activity: Q1 2025 in Review
353 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q1 2025, worth a combined $4.37B — up 39% from $3.15B a quarter earlier.
Buyers outnumbered sellers: 91 funds opened new AXSM positions and 28 closed out — a net gain of 63 holders — while 103 added to existing stakes and 115 trimmed.
The largest buyer was Assenagon Asset Management, adding an estimated $71.1M. The largest seller was RTW Investments, cutting an estimated $129M.
- 353 institutional investors held Axsome Therapeutics (AXSM) as of Q1 2025, up from 292 in Q4 2024.
- Funds reported $4.37B of Axsome Therapeutics stock for Q1 2025, up 39% quarter-over-quarter.
- 91 funds opened new Axsome Therapeutics positions in Q1 2025 and 28 closed out, a net change of +63 holders.
- The largest Axsome Therapeutics buyer in Q1 2025 was Assenagon Asset Management, an estimated $71.1M added.
- The largest Axsome Therapeutics seller in Q1 2025 was RTW Investments, an estimated $129M sold.
Based on aggregated 13F filings for Q1 2025.